OPDIVO®(nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes a...
Kusnadi E, Ng PY, George AJ, Shortt J, Bywater MJ, Poortinga G, Sanij E, Kang J, Drygin D, O'Brien S, Johnstone RW, McArthur GA, Hannan RD, Pearson RB (2016) Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma...
How to Refine Treatment Choice in Follicular Lymphoma Neoadjuvant Nivolumab/Ipilimumab Shows Early Promise for Stage III Melanoma Lenvatinib Regimen Setting Pace for Emerging Combos in Kidney Cancer PD-L1 as a Biomarker Predictive of Response to Checkpoint Inhibi...